辉瑞公司Pfizer Inc.（PFE）2025年第四季度及全年财务业绩报告「NYSE」（英文版）（27页）.pdf

1、gPfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 GuidanceFocused Execution Drives Strong Full-Year 2025 EPS PerformanceEnters 2026 with Clear Strategic Priorities and Growing Late-Stage PipelineAdvanced 11 Key Pivotal Study Starts in 2025 and 20 Key Pivotal Study Starts Planned for 20

2、26NEW YORK,Tuesday,February 3,2026 Pfizer Inc.(NYSE:PFE)reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1)provided on December 16,2025.EXECUTIVE COMMENTARYDr.Albert Bourla,Chairman and CEO of Pfizer:“With excellent execution in 20

3、25,we delivered a solid financial performance and strengthened Pfizers foundation for future growth.Looking ahead,2026 will be an important year rich in key catalysts,including our expectation for approximately 20 key pivotal study starts,and continued strategic investment to maximize our opportunit

4、ies for industry-leading growth at the end of the decade.”David Denton,CFO and EVP of Pfizer:“Im pleased with our solid financial results in 2025.With focused commercial execution,we delivered full-year operational revenue growth of 6%for our non-COVID portfolio,and our continued financial disciplin

5、e drove strong EPS performance.Today,we are reaffirming our full-year 2026 financial guidance.”OVERALL RESULTSFull-Year 2025 Revenues of$62.6 Billion,Reflecting a 2%Year-over-Year Operational Decline Excluding Contributions from Paxlovid and Comirnaty,Revenues Grew 6%OperationallyFull-Year 2025 Repo

6、rted(2)Diluted EPS of$1.36 and Adjusted(3)Diluted EPS of$3.22Fourth-Quarter 2025 Revenues of$17.6 Billion,Representing a 3%Year-over-Year Operational DeclineExcluding Contributions from Paxlovid and Comirnaty,Revenues Grew 9%OperationallyFourth-Quarter 2025 Reported(2)Diluted Loss Per Share(LPS)of$(